SCF Disease Progression Timeline Mapping | Therapeutic Temporal Windows Mapped to SCF Multi-Neurosystems Shock States (MNSS) Toxin-Induced Encephalopathy

SCF-TOX-MNSS-TEMP-0002

SCF Disease Progression Timeline Mapping

Toxin-Induced Encephalopathy

Therapeutic Temporal Windows Mapped to SCF Multi-Neurosystems Shock States (MNSS)

Integrated Neuroimmune, Neurocardiac, Neurovascular, Neurometabolic, and Neuroendocrine Collapse Framework

I. MASTER TOXIC ENCEPHALOPATHY PROGRESSION MODEL

Within the SCF framework, toxin-induced encephalopathy progresses through five interconnected shock systems:

SCF Shock System	Primary Failure
Neuroimmune Shock (NIS)	Cytokine and glial activation
Neurocardiac Shock (NCS)	Autonomic-cardiac dysregulation
Neurovascular Shock (NVS)	BBB and endothelial injury
Neurometabolic Shock (NMS)	Mitochondrial and energetic collapse
Neuroendocrine Shock (NES)	HPA-axis and neurohormonal dysfunction

These systems progress through sequential temporal windows before, during, and after encephalopathy.

II. PHASE 0 — PRE-TOXIC COMPENSATED STATE

SCF Classification

MNSS-0

Temporal Window

Months to years before clinical encephalopathy

Functional State

Compensated neuroadaptive state

Neuroimmune Status

No active inflammation

Biomarkers

Biomarker	Baseline
IL-6	<2 pg/mL
TNF-α	<5 pg/mL
IL-1β	<1 pg/mL
HMGB1	Low
YKL-40	<60 ng/mL

Neurocardiac Status

Biomarkers

Biomarker	Baseline
HRV SDNN	>100 ms
RMSSD	>30 ms
LF/HF Ratio	1–2
Troponin	Normal

Neurovascular Status

Biomarkers

Biomarker	Baseline
S100B	<0.1 ng/mL
MMP-9	<150 ng/mL
vWF	Normal

Neurometabolic Status

Biomarker	Baseline
Lactate	<2 mmol/L
ATP Production	Normal
cf-mtDNA	Low

Neuroendocrine Status

Biomarker	Baseline
Cortisol	Physiologic
ACTH	Physiologic
DHEA-S	Age-adjusted normal

Therapeutic Window

Preventative surveillance

Reversibility:

Very High

III. PHASE 1 — TOXIC EXPOSURE PRIMING

SCF Classification

MNSS-I

Temporal Window

Hours to days after toxin exposure

Dominant Shock State

Neuroimmune Shock Initiation

Neuroimmune Shock

Pathophysiology

Microglial priming
Cytokine activation
Astrocytic stress

Biomarkers

Biomarker	Change
IL-6	↑ 20–100%
TNF-α	↑
HMGB1	↑
YKL-40	↑
MCP-1	↑

Neurocardiac Shock

Biomarkers

Biomarker	Change
SDNN	↓10–20%
RMSSD	↓
LF/HF Ratio	↑

Neurovascular Shock

Biomarkers

Biomarker	Change
MMP-9	↑
S100B	Mild ↑
VEGF	↑

Neurometabolic Shock

Biomarkers

Biomarker	Change
Lactate	Mild ↑
Lactate/Pyruvate Ratio	↑
ATP Production	↓10%

Neuroendocrine Shock

Biomarkers

Biomarker	Change
Cortisol	↑
ACTH	↑
DHEA-S	↓

Clinical Symptoms

Fatigue
Brain fog
Sleep disturbance
Reduced concentration

Therapeutic Window

Maximum reversibility

SCF-PCR

Preventative intervention phase

IV. PHASE 2 — EARLY TOXIC ENCEPHALOPATHY

SCF Classification

MNSS-II

Temporal Window

24–72 hours

Dominant Shock State

Neuroimmune-Neurovascular Coupling Failure

Neuroimmune Shock

Biomarker	Change
IL-6	↑↑
TNF-α	↑↑
IL-1β	↑
HMGB1	↑↑

Neurovascular Shock

Biomarker	Change
MMP-9	↑↑
S100B	↑
Claudin-5 Fragments	↑
Albumin Quotient	↑

Neurocardiac Shock

Biomarker	Change
SDNN	↓20–40%
RMSSD	↓
LF/HF Ratio	>3

Neurometabolic Shock

Biomarker	Change
Lactate	2–4 mmol/L
ATP Production	↓20–30%
cf-mtDNA	↑

Neuroendocrine Shock

Biomarker	Change
Cortisol	Persistent elevation
ACTH	Dysregulated
Vasopressin	↑

Clinical Symptoms

Confusion
Delirium
Memory deficits
Slowed cognition

Therapeutic Window

High reversibility

V. PHASE 3 — ESTABLISHED TOXIC ENCEPHALOPATHY

SCF Classification

MNSS-III

Temporal Window

Days to weeks

Dominant Shock State

Multi-System Neuroconnectomic Shock

Neuroimmune Shock

Biomarker	Change
IL-6	↑↑↑
TNF-α	↑↑
CXCL10	↑
YKL-40	↑↑

Neurovascular Shock

Biomarker	Change
MMP-9	↑↑↑
vWF	↑
Syndecan-1	↑
VEGF	↑

Neurocardiac Shock

Biomarker	Change
SDNN	<80 ms
RMSSD	↓↓
Troponin	Mild ↑
NT-proBNP	↑

Neurometabolic Shock

Biomarker	Change
Lactate	>4 mmol/L
ATP Production	↓40%
CoQ10	↓
cf-mtDNA	↑↑

Neuroendocrine Shock

Biomarker	Change
Cortisol Rhythm	Lost
DHEA-S	↓↓
Melatonin	↓

Neuroinjury Biomarkers

Biomarker	Change
GFAP	↑↑
NfL	↑
UCH-L1	↑
NSE	↑

Connectomic Findings

DMN disruption
Salience network instability
Executive network collapse

Therapeutic Window

Moderate reversibility

VI. PHASE 4 — ACUTE MULTI-NEUROSYSTEMS SHOCK

SCF Classification

MNSS-IV

Temporal Window

Hours to days

Dominant Shock State

Global Connectomic Collapse

Neuroimmune Shock

Biomarker	Status
IL-6	Peak
TNF-α	Peak
HMGB1	Peak

Neurovascular Shock

Biomarker	Status
MMP-9	Peak
S100B	Peak
Albumin Quotient	Peak

Neurocardiac Shock

Biomarker	Status
SDNN	<50 ms
RMSSD	Severely reduced
Troponin	Elevated
NT-proBNP	Elevated

Neurometabolic Shock

Biomarker	Status
Lactate	>5 mmol/L
ATP Production	↓50–70%
cf-mtDNA	Peak

Neuroendocrine Shock

Biomarker	Status
Cortisol	Extreme dysregulation
ACTH	Abnormal
Vasopressin	Markedly elevated

Neuroinjury Biomarkers

Biomarker	Status
GFAP	Peak
NfL	Peak
UCH-L1	Peak
NSE	Peak

Clinical Features

Severe encephalopathy
Stupor
Coma
Seizures
Respiratory depression
Autonomic instability

Therapeutic Window

Limited

Highest mortality risk

VII. PHASE 5 — RECOVERY INITIATION

SCF Classification

MNSS-R1

Temporal Window

Days to weeks

Dominant Shock State

Controlled Resolution

Biomarker Trends

Biomarker	Recovery Trend
IL-6	↓
TNF-α	↓
HMGB1	↓
GFAP	↓
S100B	↓
Lactate	↓
HRV	↑

Therapeutic Window

High

Primary restorative period

VIII. PHASE 6 — CONNECTOMIC RECONSTRUCTION

SCF Classification

MNSS-R2

Temporal Window

Weeks to months

Biomarker Trends

Biomarker	Recovery Trend
NfL	↓
GFAP	↓
qEEG Connectivity	↑
DTI FA	↑
HRV SDNN	↑
Cortisol Rhythm	Normalizing

Therapeutic Window

Optimal neurorestorative phase

IX. PHASE 7 — POST-ENCEPHALOPATHY ADAPTIVE STATE

SCF Classification

MNSS-R3

Temporal Window

Months to years

Residual Risk Biomarkers

Biomarker	Persistent Elevation Suggests
NfL	Chronic axonal injury
GFAP	Persistent astrocytosis
YKL-40	Chronic glial activation
HRV Suppression	Chronic autonomic dysfunction
DHEA-S Reduction	Neuroendocrine maladaptation
qEEG Dysconnectivity	Residual connectomic injury

X. THERAPEUTIC TEMPORAL WINDOW MATRIX

SCF Phase	Shock State	Reversibility	Primary Biomarkers	Therapeutic Objective
MNSS-0	Compensated	Very High	Baseline panel	Prevention
MNSS-I	Neuroimmune Priming	Very High	IL-6, TNF-α, HRV	Early interception
MNSS-II	Neuroimmune-Neurovascular Shock	High	MMP-9, S100B, Lactate	Prevent progression
MNSS-III	Multi-System Shock	Moderate	GFAP, NfL, HRV	Stabilization
MNSS-IV	Global Collapse	Limited	Peak GFAP/NfL/Lactate	Life preservation
MNSS-R1	Resolution	High	Falling cytokines	Recovery initiation
MNSS-R2	Reconstruction	Moderate-High	qEEG, DTI, HRV	Neurorestoration
MNSS-R3	Adaptation	Variable	Residual biomarkers	Long-term resilience

XI. SCF UNIVERSAL TOXIN-INDUCED ENCEPHALOPATHY EARLY WARNING PANEL

Earliest Predictive Biomarkers

IL-6
TNF-α
HMGB1
MMP-9
YKL-40
HRV SDNN
Lactate/Pyruvate Ratio
Cortisol Rhythm Distortion
cf-mtDNA

These biomarkers consistently precede overt encephalopathy and define the highest-value intervention window within the SCF Multi-Neurosystems Shock State model.

MASTER REGISTRY INDEX

SCF-TOX-MNSS-TEMP-0002 — Toxic Encephalopathy Disease Progression Timeline Mapping
SCF-MNSS-0001 — Multi-Neurosystems Shock State Framework
SCF-ECCA-TOX-0001 — Toxic Encephalopathy Module
SCF-ECCA-0001 — Encephalopathy Connectomic Collapse Atlas
SCF-BIOMARKER-ENDPOINTS-0001 — Biomarker Endpoint Validation Framework
SCF-CONNECTOMIC-RECONSTRUCTION-0001 — Neuroimmune Connectomic Reconstruction Framework
SCF-ACU-NEURO-ATLAS-0001 — SCF Neural Mapping Schema